• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Current Colorectal Cancer Reports >Do We Need another Antiangiogenesis Agent for Colorectal Cancer: are Bevacizumab and Aflibercept the Same?
【24h】

Do We Need another Antiangiogenesis Agent for Colorectal Cancer: are Bevacizumab and Aflibercept the Same?

机译：我们是否需要另一种抗结直肠癌的抗血管生成剂：贝伐单抗和阿柏西普是否相同？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Colorectal cancer (CRC) is a major cause of cancer-related mortality worldwide. Treatment of metastatic disease has improved survival in recent years. Angiogenesis is a multistep process, and the two most potent regulatory molecules stimulating the formation of new blood vessels are vascular endothelial growth factor (VEGF) and beta fibroblast growth factor (bFGF). Bevacizumab, a recombinant monoclonal antibody that inactivates VEGF-A, was the first antiangiogenic treatment approved for use against metastatic CRC. Aflibercept, also known as VEGF-trap, is a fully humanized recombinant protein that targets VEGF-A, VEGF-B, and placental growth factor-1 (PlGF). Bevacizumab is approved for first and second-line treatment associated with chemotherapy, and aflibercept has recently been approved for second-line treatment associated with irinotecan-based chemotherapy. Their mechanism of action and the preclinical and clinical data for both treatments will be reviewed in this article, with emphasis on their developmental process and their current and future use for treating CRC.
机译：大肠癌（CRC）是全球范围内与癌症相关的死亡率的主要原因。近年来，转移性疾病的治疗提高了生存率。血管生成是一个多步骤过程，刺激新血管形成的两个最有效的调节分子是血管内皮生长因子（VEGF）和β成纤维细胞生长因子（bFGF）。贝伐单抗是一种使VEGF-A失活的重组单克隆抗体，是首个被批准用于抗转移性CRC的抗血管生成治疗。 Aflibercept，也称为VEGF-trap，是靶向VEGF-A，VEGF-B和胎盘生长因子1（PlGF）的完全人源化重组蛋白。贝伐单抗被批准用于与化学疗法有关的一线和二线治疗，而阿柏西普最近已被批准用于与基于伊立替康的化学疗法相关的二线治疗。本文将对它们的作用机理以及两种治疗方法的临床前和临床数据进行综述，重点是它们的发展过程以及它们目前和将来在治疗CRC中的用途。

著录项

  • 来源
    《Current Colorectal Cancer Reports》 |2013年第4期|317-325|共9页
  • 作者

    Maria Ignez Braghiroli; Rachel P. Riechelmann; Jorge Sabbaga; Paulo M. Hoff;

  • 作者单位

    Centro de Oncologia do Hospital Sírio Libanês">(1);

    Instituto do Câncer do Estado de São Paulo do Hospital das Clínicas da Faculdade de Medicina de Universidade de São Paulo">(2);

    Centro de Oncologia do Hospital Sírio Libanês">(1);

    Centro de Oncologia do Hospital Sírio Libanês">(1);

    Instituto do Câncer do Estado de São Paulo do Hospital das Clínicas da Faculdade de Medicina de Universidade de São Paulo">(2);

    Centro de Oncologia do Hospital Sírio Libanês">(1);

    Instituto do Câncer do Estado de São Paulo do Hospital das Clínicas da Faculdade de Medicina de Universidade de São Paulo">(2);

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    Metastatic colorectal cancer; Angiogenesis; Bevacizumab; Aflibercept; VEGF; PIGF; Molecularly targeted therapy;

    机译：转移性结直肠癌;血管生成;贝伐单抗;阿柏西普;VEGF;PIGF;分子靶向治疗;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号